Abstracts Archive - Page 13 of 1683 - ATC Abstracts

2022 American Transplant Congress
Impact of Cold Ischemia Times on 1 Year Kidney Transplant Outcomes
T. Fletchinger, L. Burdine
Department of Surgery, University of Arkansas for Medical Sciences, Little Rock, AR
*Purpose: Recent organ allocation changes have increased travel and subsequent cold ischemia times (CIT) of kidney allografts. We sought to investigate the impact of prolonged…
2022 American Transplant Congress
Chronic Ethanol Exposure Prolongs Murine Allograft Survival
D. Swift, M. Ford, W. Kitchens
Department of Surgery, Emory University, Atlanta, GA
*Purpose: Alcoholic liver disease is the leading indication for liver transplantation in the United States, and patients are increasingly transplanted without the traditional six month…
2022 American Transplant Congress
Sirolimus Regimens After Kidney Transplantation: Role of Pre-Transplant Risk Factors in Modifying the Risk of Mortality in Adult Recipients
A. Santos¹, H. Ibrahim¹, M. A. Leghrouz¹, X. Wen²
¹University of Florida, Gainesville, FL, ²University of Rhode Island, Kinston, RI
*Purpose: We aimed to investigate the role of risk factors in modifying the association of sirolimus with mortality in kidney transplant (KT) recipients (KTRs).*Methods: Using…
2022 American Transplant Congress
Results Of The Ctot19 Trial: Infliximab (IFX) Induction Does Not Impact 2-year Outcomes In Deceased Donor Kidney Transplant Recipients
P. Heeger¹, B. Armstrong², T. Alhamad³, D. Brennan⁴, J. Bromberg⁵, S. Bunnapradist⁶, S. Chandran⁷, R. Fairchild⁸, D. Foley⁹, R. Formica¹⁰, I. W. Gibson¹¹, D. Hricik¹², K. Kesler², R. B. Mannon¹³, M. Menon¹⁰, K. Newell¹⁴, P. Nickerson¹¹, J. Odim¹⁵, E. Poggio⁸, R. Sung¹⁶, R. Shapiro¹, K. Tinckam¹⁷, F. Vincenti⁷
¹Mount Sinai, New York, NY, ²Rho, Durham, NC, ³Washington U, Saint Louis, MO, ⁴Johns Hopkins, Baltimore, MD, ⁵U Maryland, Baltimore, MD, ⁶UCLA, Los Angeles, CA, ⁷UCSF, San Francisco, CA, ⁸Cleveland Clinic, Cleveland, OH, ⁹U Wisconsin, Madison, WI, ¹⁰Yale, New Haven, CT, ¹¹U Manitoba, Winnipeg, MB, Canada, ¹²U Hosp Case, Cleveland, OH, ¹³U Nebraska, Omaha, NE, ¹⁴Emory, Atlanta, GA, ¹⁵NIAID NIH, Rockville, MD, ¹⁶U Michigan, Ann Arbor, MI, ¹⁷U Hlth Network, Toronto, ON, Canada
*Purpose: Ischemia-reperfusion (IR) of a kidney transplant (KTx) up-regulates tumor necrosis factor alpha (TNF) production within the allograft. IR-induced TNF amplifies post-KTx allograft inflammation and…
2022 American Transplant Congress
HLA-II Subclasses Behave Differently Between Themselves and Between Humans: Cues to Understand Alloreactivity
S. Beland, O. Desy, M. Marcoux, M. Thivierge, J. Desgagnes, S. A. De Serres
Transplantation Unit, Renal Division, University Health Center of Quebec, Faculty of Medicine, Universite Laval, Quebec, QC, Canada
*Purpose: De novo anti-HLA-II DSAs (dnDSA) are associated with antibody-mediated rejection. However, some patients with anti-HLA-II DSAs will not develop rejection, suggesting that the development…
2022 American Transplant Congress
Reducing Financial Burden for Living Donors: A Single Center Experience of Increased National Living Donor Assistance Center (NLDAC) Support
T. Klair, K. Throgmorton, D. Oviedo, E. Cepeda
Transplant Center, University of Texas Health San Antonio, San Antonio, TX
*Purpose: National Living Donor Assistance Center (NLDAC) offers assistance to overcome some of the financial barriers associated with Living Donation. From 2015 to 2020, an…
2022 American Transplant Congress
SARS-CoV-2 Infection is Associated with Greater Neutralizing Antibody Response Compared to Three Doses of Mrna-1273 Vaccine in Solid Organ Transplant Recipients
V. H. Ferreira, V. Hall, T. M. Marinelli, M. Ierullo, V. Kulasingam, A. Humar, D. Kumar
University Health Network, Toronto, ON, Canada
*Purpose: Prior studies suggest that two doses of mRNA vaccine in SOTR may result in lower antibody and T-cell responses relative to levels seen following…
2022 American Transplant Congress
Stem Cell Donor-Derived CPRA Better Reflects Sensitization Than Current CPRA
K. Lindblad¹, C. Murphey², P. Lalli³, J. Lunz⁴, L. Gragert⁵
¹UNOS, Richmnd, VA, ²Southwest Immunodiagnostics, Inc., San Antonio, TX, ³Carolinas Medical Center, Charlotte, NC, ⁴LifeLink Foundation Transplant Immunology Lab, Tampa, FL, ⁵Tulane University School of Medicine, New Orleans, LA
*Purpose: The OPTN Histocompatibility Committee proposes replacing the current calculated panel reactive antibody (CPRA), based on HLA haplotype frequencies from ~14,000 deceased kidney donors, with…
2022 American Transplant Congress
Safety and Efficacy of Early Central Line Removal in Post Liver Transplant Patients
T. Shamaa¹, E. MacLean¹, O. Shamaa², Z. Lu¹, A. Hinge³, S. Saymuah³, A. Mohamed⁴, T. Kitajima⁴, S. Nagai⁴, M. Rizzari⁴, A. Yoshida⁴, M. Abouljoud⁴, K. Collins⁴
¹General Surgery, Henry Ford Hospital, Detroit, MI, ²Internal Medicine, Henry Ford Hospital, Detroit, MI, ³Wayne State University School of Medicine, Detroit, MI, ⁴Henry Ford Transplant Institute, Detroit, MI
*Purpose: Avoiding central line-associated infections (CLABSIs) is paramount in liver transplant recipients. As a hospital-wide infection control initiative at our institution, early removal of central…
2022 American Transplant Congress
Generation and Functional Characterization of Bio-Engineered Livers for Heterotopic Implantation in Porcine Model of Acute Liver Failure
A. A. Katane¹, B. P. Amiot², A. R. Stumbras¹, A. Mendenhall¹, N. R. Palumbo¹, A. C. Donepudi¹, J. J. Ross¹, S. L. Nyberg³
¹Miromatrix Medical Inc, Eden Prairie, MN, ²Department of Surgery, Mayo Clinic, Rochester, MN, ³William J. von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, MN
*Purpose: Liver transplantation has shown to be an effective therapy for the end-stage liver diseases (ESLD). However, as donor organ shortages increase, organ engineering technology…